Globally, liver cancer rates continue to climb, is the second leading cause of cancer death. Liver death is the 10th leading cause of death. About 70% of Hepatocellular Carcinoma (HCC) cases are caused by viral hepatitis B (HBV) and C (HCV). Over 350 million people in the world are living with hepatitis B and C, putting them at risk of cirrhosis, liver failure and liver cancer. Hepatitis viruses are bloodborne transmitted. HBV is most commonly transmitted from mother to child during birth, also through contact with blood or body fluids, during sex with an infected partner, unsafe injections or exposures to sharp instruments. The development of chronic infection is common in infants infected from their mothers or before the age of 5 years. Today all infants receive hepatitis B vaccine after birth, with additional 2 doses to complete the series, and protection lasts at least 20 years.  Chronic hepatitis B can be treated with oral antiviral agents (tenofovir or entecavir) to suppress HBV. Treatment can slow the progression of cirrhosis, reduce incidence of liver cancer and improve long term survival. Most HCV infection occur through exposure to blood from unsafe injection practices, unsafe health care, unscreened blood transfusions, injection drug use. Approximately 70% of infection will develop chronic infection, and leading to the cirrhosis, cancer. Today pan-genotypic direct-acting antivirals (DAAs) therapy can cure more than 95% of persons with hepatitis C, but access to diagnosis and treatment is low. There is currently no effective vaccine against HCV infection.
　　In 2016, WHO’s World Health Assembly called for global elimination of viral hepatitis by 2030 and set global targets of achieving 90% reduction in new cases of hepatitis B and hepatitis C, a 65% reduction in deaths from hepatitis B and hepatitis C, and treatment of 80% of people living with these infections. WHO is working in the following areas to support countries in moving towards achieving the global hepatitis goals under the Sustainable Development Agenda 2030: 1) raising awareness, promoting partnerships and mobilizing resources; 2) formulating evidence-based policy and data for action; 3) preventing transmission; and 4) scaling up screening, care and treatment services. In 2020, global coverage of three doses of hepatitis B vaccine was 83%, and 42% of children received birth dose, which is essential to prevent mother-to-child transmission. Improving rates of infant vaccination coverage, especially in African region, will reduce HBV infection, which could help reduce liver disease and death. Athough affordable, effective treatments can prevent liver disease and liver cancer among people living with hepatitis B or C, one of the largest gaps for elimination is “finding the missing millions.”  In 2019, globally only 10% of those with hepatitis B and only 21% of people with hepatitis C have been diagnosed. Of these diagnosed, 22% and 62% had received treatment, respectively. To reach elimination, we must scale up universal Hepatitis screening.  Point of care tests exist for hepatitis B and C, and we must push for usage, especially in community settings. Screening in primary care and across various care settings is critical to reaching more people. Another critical gap is the low treatment rates. Worldwide, only 13% of people living with hepatitis C and 2% of people living with hepatitis B have received treatment. Global costs of antiviral medications have fallen, however, how to improve the cascade of care with a focus on treatment simplification, task shifting and decentralizing of care to primary care setting in order to expand access need commitment and resource. Taiwan started universal HBV newborn vaccination in 1982, implemented universal health care, digitalized health information in 1995, began national HBV antiviral therapy 2004 and national HCV therapy 2018. Taiwan model is ahead and on the track toward elimination of hepatitis B and C by 2030.